Anzeige
Mehr »
Login
Dienstag, 15.04.2025 Börsentäglich über 12.000 News von 690 internationalen Medien
Global Tactical tritt dem Critical Minerals Institute bei!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A0DLB7 | ISIN: CA88337V1004 | Ticker-Symbol: TTX
Stuttgart
15.04.25
08:01 Uhr
0,120 Euro
0,000
0,00 %
Branche
Gesundheitswesen
Aktienmarkt
Sonstige
1-Jahres-Chart
THERALASE TECHNOLOGIES INC Chart 1 Jahr
5-Tage-Chart
THERALASE TECHNOLOGIES INC 5-Tage-Chart
RealtimeGeldBriefZeit
0,1210,14012:46

Aktuelle News zur THERALASE Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
00:54Theralase Technologies Inc: Theralase closes $419,124 private placement1
MoTheralase Technologies Inc.: Theralase(R) Closes Non-Brokered Private Placement256Toronto, Ontario--(Newsfile Corp. - April 14, 2025) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage pharmaceutical company dedicated to the...
► Artikel lesen
DoTheralase Technologies Inc: Theralase treats herpes-infected mice with ruvidar1
DoTheralase Technologies Inc.: Ruvidar More Effective in the Treatment of Herpes than FDA-Approved Treatments168Toronto, Ontario--(Newsfile Corp. - April 10, 2025) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage pharmaceutical company dedicated to the...
► Artikel lesen
07.04.Theralase Technologies Inc: Theralase sees patient complete response in NMIBC study1
07.04.Theralase Technologies Inc.: Ruvidar Demonstrates 7 Year Complete Response222Toronto, Ontario--(Newsfile Corp. - April 7, 2025) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage pharmaceutical company dedicated to the...
► Artikel lesen
THERALASE Aktie jetzt für 0€ handeln
24.03.Theralase Technologies Inc: Theralase talks efficacy of Ruvidar in HSV-1 treatment2
24.03.Theralase's Ruvidar excels in preclinical herpes treatment1
24.03.Theralase Technologies Inc.: Ruvidar Effective in the Treatment of Herpes284Toronto, Ontario--(Newsfile Corp. - March 24, 2025) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage pharmaceutical company dedicated to the...
► Artikel lesen
20.03.Theralase Technologies Inc: Theralase 1,034,002-share private placement8
12.03.Theralase Technologies Inc.: Theralase(R) Releases 2024 Annual Financial Statements208Toronto, Ontario--(Newsfile Corp. - March 12, 2025) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage pharmaceutical company dedicated to the...
► Artikel lesen
11.03.Theralase Technologies Inc: Theralase closes $310,200 private placement7
11.03.Theralase Technologies Inc.: Theralase(R) Closes Non-Brokered Private Placement305Toronto, Ontario--(Newsfile Corp. - March 11, 2025) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage pharmaceutical company dedicated to the...
► Artikel lesen
10.03.Theralase Technologies Inc: Theralase data show functions improve with TLC-24001
10.03.Theralase Technologies Inc.: Theralase(R) Therapy Improves Motor and Non-Motor Function in Parkinson's Patients224Toronto, Ontario--(Newsfile Corp. - March 10, 2025) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage pharmaceutical company dedicated to the...
► Artikel lesen
06.03.Buzz on the Bullboards: Stocks making headlines - Baytex, New Found Gold, Theralase7
26.02.Theralase Technologies Inc: Theralase sees case of tumour regression with Rutherrin13
25.02.Theralase Technologies Inc.: Theralase(R) Demonstrates Efficacy of Rutherrin(R) in Destruction of Non-Hodgkin's Lymphoma322Toronto, Ontario--(Newsfile Corp. - February 25, 2025) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage pharmaceutical company dedicated to...
► Artikel lesen
13.02.Theralase Technologies, Inc.: Theralase Demonstrates Effective Treatment of Herpes505Theralase® validates previous University of Manitoba research by demonstrating that RuvidarTM is safe and effective in the treatment of the Herpes Simplex Virus in an animal model. TORONTO, ON / ACCESS...
► Artikel lesen
12.02.Theralase Technologies Inc: Theralase says U of M research on Ruvidar validated3
Seite:  Weiter >>
50 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1